More than 900 attendees from 47 countries convene in Seattle for AIDS
Vaccine 2007 Conference
SEATTLE, Aug. 20 /PRNewswire/ -- More than 900 global researchers, clinicians, and specialists convene this week for the AIDS Vaccine 2007 Conference at the Sheraton Seattle Hotel and Towers. Since the AIDS Vaccine 2000 Conference in Paris, this event has emerged as the premier forum for the exchange of scientific information relating to the difficult task of developing an effective vaccine against HIV.
"It has become clear that a preventive vaccine is essential to controlling the global AIDS epidemic," says conference chair Dr. Lawrence Corey. "The conference provides a venue for the full-scale international, interdisciplinary collaboration which is critical to the development of a global AIDS vaccine."
The week-long conference which concludes on Aug. 23 will examine the entire spectrum of issues in AIDS vaccine development and deployment: including, the global effort in preventative and therapeutic vaccines, the potential development of pediatric and adolescent vaccines, clinical trials in emerging countries, and the need for strong political and financial commitment to support the scientific development of a vaccine against AIDS.
The location of the conference in Seattle is reflective of the Pacific Northwest's international leadership in the development of an AIDS vaccine. Seattle organizations contributing to the conference include the Fred Hutchinson Cancer Research Center's HIV Vaccine Trials Network, the Seattle Biomedical Research Institute, the University of Washington and the Bill & Melinda Gates Foundation.
AIDS Vaccine 2007 is the first conference to be organized under the
auspices of the Global HIV Vaccine Enterprise,
(http://www.hivvaccineenterprise.org) an alliance of independent organizations
around the world dedicated to accelera
|SOURCE The AIDS Vaccine 2007 Conference|
Copyright©2007 PR Newswire.